×

Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus

  • US 20090324613A1
  • Filed: 03/10/2009
  • Published: 12/31/2009
  • Est. Priority Date: 03/10/2008
  • Status: Active Grant
First Claim
Patent Images

1. An isolated anti-CMV antibody or fragment thereof, wherein said antibody comprises:

  • I;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO;

         36);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISSDGDDDRYADSVKG (SEQ ID NO;

         37);

    (iii) a VH CDR3 region comprising the amino acid sequence of DGRCGEPKCYSGLPDY (SEQ ID NO;

         38); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO;

         43);

    (ii) a VL CDR2 region comprising the amino acid sequence of DASNRAT (SEQ ID NO;

         44);

    (iii) a VL CDR3 region comprising the amino acid sequence of LQRNTWPPLT (SEQ ID NO;

         45);

    II;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SNYGMH (SEQ ID NO;

         48);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISSDGSNEHYADSVKG (SEQ ID NO;

         49);

    (iii) a VH CDR3 region comprising the amino acid sequence of DGRCPDVNCYSGLIDY (SEQ ID NO;

         50); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYLA (SEQ ID NO;

         53);

    (ii) a VL CDR2 region comprising the amino acid sequence of DASNRAT (SEQ ID NO;

         44);

    (iii) a VL CDR3 region comprising the amino acid sequence of QQRSNWPPLT (SEQ ID NO;

         54);

    III;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SSNGIH (SEQ ID NO;

         57);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISSDANDKQYADSVKG (SEQ ID NO;

         58);

    (iii) a VH CDR3 region comprising the amino acid sequence of DGTCSGGNCYSGLIDY (SEQ ID NO;

         59); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO;

         43);

    (ii) a VL CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO;

         64);

    (iii) a VL CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO;

         65);

    IV;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO;

         36);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNAHYADSVRG (SEQ ID NO;

         68);

    (iii) a VH CDR3 region comprising the amino acid sequence of EGRCIEENCYSGQIDY (SEQ ID NO;

         69); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYMA (SEQ ID NO;

         74);

    (ii) a VL CDR2 region comprising the amino acid sequence of DASIRAT (SEQ ID NO;

         75);

    (iii) a VL CDR3 region comprising the amino acid sequence of QQRSSWPPLT (SEQ ID NO;

         76);

    V;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO;

         36);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNAHYADSVRGR (SEQ ID NO;

         79);

    (iii) a VH CDR3 region comprising the amino acid sequence of EGRCIEEKCYSGQIDY (SEQ ID NO;

         80); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYMA (SEQ ID NO;

         74);

    (ii) a VL CDR2 region comprising the amino acid sequence of DASIRAT (SEQ ID NO;

         75);

    (iii) a VL CDR3 region comprising the amino acid sequence of QQRSSWPPLT (SEQ ID NO;

         76);

    VI;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SDYGMH (SEQ ID NO;

         85);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNTHYADSVRG (SEQ ID NO;

         86);

    (iii) a VH CDR3 region comprising the amino acid sequence of DGKCPDLKCYSGLIDY (SEQ ID NO;

         87);

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO;

         43);

    (ii) a VL CDR2 region comprising the amino acid sequence of DASKRAT (SEQ ID NO;

         92);

    (iii) a VL CDR3 region comprising the amino acid sequence of HQRSSWPPLT (SEQ ID NO;

         93);

    VII;

    (a) a VH region comprising(i) a VH CDR1 region comprising the amino acid sequence of SXXGXH (SEQ ID NO;

         95), SXXGIH (SEQ ID NO;

         98), or SXYGMH (SEQ ID NO;

         101);

    (ii) a VH CDR2 region comprising the amino acid sequence of VISXDXXXXXYADSVRG (SEQ ID NO;

         96) or VISXDGXNXHYADSVXG (SEQ ID NO;

         99);

    (iii) a VH CDR3 region comprising the amino acid sequence of DGXCSXXXCYSGLXDY (SEQ ID NO;

         100), EGRCIEEXCYSGQIDY (SEQID NO;

         102), or DGXCPDXXCYSGLIDY (SEQ ID NO;

         103); and

    (b) a VL region comprising(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGXYXA (SEQ ID NO;

         111) or RASQSVGXYLA (SEQ ID NO;

         114);

    (ii) a VL CDR2 region comprising the amino acid sequence of XASXRAT (SEQ ID NO;

         112) or DASXRAT (SEQ ID NO;

         115);

    (iii) a VL CDR3 region comprising the amino acid sequence of XQRXXWPPLT (SEQ ID NO;

         113), HQRSXWPPLT (SEQ ID NO;

         116), or QQRSXWPPLT (SEQ ID NO;

         117).

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×